Mylan Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs

MYL 15.86

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tenpoint who wrote (324)	6/10/1998 7:16:00 PM
From: khalid jaffar	of 384

Upgrade: Mylan Laboratories (MYL) 31 1/8 +3/16: Gruntal & Co. reiterates "strong buy" on generic drug company as the company receives FDA approval for its branded burn treatment product, Sulfamyloa; has a 12-month price target of $40 a share; an exclusive unique product, Sulfamyloa could generate sales of $10 mln in the first year and peak around $50 mln; Sulfamyloa addresses the third-degree burn market which is largely under served; MYL to receive seven years of marketing exclusivity; projects MYL to earn $1.20 in FY99 and $1.45 in FY00..... from briefing.com briefing.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next